Paredes AR

Idioma: Español
Referencias bibliográficas: 18
Paginas: 87-91
Archivo PDF: 147.69 Kb.

RESUMEN

Las indicaciones de PFC son limitadas y específicas: es un recurso que no debe utilizarse indiscriminadamente. Los defectos de coagulación específicos deben tratarse con factor hemoderivado o recombinante y no con PFC. El PFC no está indicado como expansor plasmático. El PFC no debe utilizarse como profilaxis o para tratar de corregir pruebas de coagulación anormales si el paciente no presenta manifestaciones de sangrado activo. Hacen falta más estudios prospectivos aleatorizados para valorar la utilidad del PFC en diversas situaciones clínicas. Es necesario contar con nuevos métodos menos costosos para la eliminación de patógenos potenciales. Se requiere un mayor conocimiento de las interacciones complejas entre endotelio vascular, proteínas de la coagulación, citocinas proinflamatorias y sistema fibrinolítico para una mejor comprensión del mecanismo de la hemostasia.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Spence RK. Clinical use of plasma and plasma fractions. Best Practice and Research Clinical Haematology 2006; 19: 83-96.

2. Kakaiya RM, Morse EE, Panek S. Labile coagulation factors in thawed fresh frozen plasma prepared by two 0methods. Vox Sang 1984; 46: 44-46.

3. Novis DA, Renner S, Friedberg RC et al. Quality indicators of fresh frozen plasma and platelet utilization. Arch Pathol Lab Med 2002; 126: 527-532.

4. Solheim BG, Flesland O, Brosstad F et al. Improved preservation of coagulation factors after pre-storage leukocyte depletion of whole blood. Transfus Apheresis Sci 2003; 29: 133-139.

5. Hoots WK, Abrams C, Tankersley D. The food and drug administration’s perspective on plasma safety. Transfus Med Rev 2001; 15: 20-26.

6. Williamson LM, Allain JP. Virally inactivated fresh frozen plasma. Vox Sang 1995; 69: 159-165.

7. Fischer G, Hoots WK, Abrams C. Viral reduction techniques: types and purpose. Transfus Med Rev 2001; 15: 27-39.

8. Hilfenhaus J, Groner A, Novak T, Weiner T. Analysis of human plasma products: Polymerase chain reaction does not discriminate between live and inactivated viruses. Transfusion 1997; 37: 935-940.

9. Beek H, Hellstern P. In vitro characterization of solvent/detergent-treated plasma and of quarantine fresh frozen plasma. Vox Sang 1998; 74: 219-223.

10. Hellstern P, Haubelt H. Manufacture and composition of fresh frozen plasma and Virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 2002; 107: 53-58.

11. Wieding JU, Hellstern P, Kohler M. Inactivation of viruses in fresh frozen plasma. Ann Hematol 1993; 67: 259-266.

12. Doyle S, O’Brien P, Murphy K et al. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coag Fibrinolysis 2003; 14: 283-287.

13. Suontaka AM, Blomback M, Chapman J. Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion 2003; 43: 568-575.

14. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent/detergent-treated plasma. In search of a zero-risk blood supply. JAMA 1994; 272: 1210-1214.

15. Standworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. American Society of Hematology. Education Program book 2007: 179-186.

16. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45: 1413-1425.

17. Peterson GA. Does systematic anticoagulation increase the risk of internal yugular vein cannulation? (letter) Anesthesiology 1991; 75: 1124.

18. Ewe K. Bleeding after liver biopsy does not correlate with indices of pertipheral coagulation. Dig Dis Sci 1981; 26: 388-393.